Inhibrx Biosciences, Inc. 8-K

What Happened
Inhibrx Biosciences, Inc. (INBX) filed a Form 8-K on March 19, 2026 to disclose its results of operations and financial condition, announcing the company's financial results for the year ended December 31, 2025. The company furnished a press release with the results as Exhibit 99.1 to the filing. The report was signed by Kelly Deck, Chief Financial Officer.

Key Details

• Filing date: March 19, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: Year ended December 31, 2025 (annual financial results / earnings announcement).
• Exhibit: Press release announcing the results furnished as Exhibit 99.1.
• Administrative: Cover page interactive data file included (Inline XBRL) and signature by CFO Kelly Deck.

Why It Matters
This 8-K is the company’s official disclosure of its 2025 annual financial results (earnings/revenue and related metrics will be detailed in the attached press release). Retail investors should read the Exhibit 99.1 press release and any subsequent SEC filings for the specific financial figures, trends, and management commentary to assess impacts on valuation, cash runway, and near‑term strategy.